We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+6.48%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.13B
AUM Growth
+$1.04B
Cap. Flow
+$940M
Cap. Flow %
44.08%
Top 10 Hldgs %
46.5%
Holding
110
New
45
Increased
37
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$98.6M
2
GILD icon
Gilead Sciences
GILD
+$96.5M
3
PFE icon
Pfizer
PFE
+$46.4M
4
JNJ icon
Johnson & Johnson
JNJ
+$33.9M
5
ABBV icon
AbbVie
ABBV
+$26.7M

Top Sells

Rank Stock Value
1
FRX
FOREST LABORATORIES INC
FRX
+$10.9M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.11M
3
AEGR
Aegerion Pharmaceuticals
AEGR
+$1K

Sector Composition

Rank Sector Weight
1 Healthcare 81.82%
2 Real Estate 2.39%
3 Financials 1.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$163B
$265M 12.43%
2,490,531
+985,819
+66% +$96.5M
CELG
2
DELISTED
Celgene Corp
CELG
$193M 9.05%
2,036,434
+1,092,342
+116% +$98.6M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$122B
$78.8M 3.7%
701,944
+161,000
+30% +$15.3M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$74.9M 3.51%
451,905
+116,006
+35% +$19.1M
AMGN icon
5
Amgen
AMGN
$209B
$71.6M 3.36%
510,042
+60,499
+13% +$7.9M
REGN icon
6
Regeneron Pharmaceuticals
REGN
$77.4B
$67.5M 3.16%
187,166
-6,300
-3% -$2.11M
AGN
7
DELISTED
Allergan plc
AGN
$67M 3.14%
277,631
+71,924
+35% +$16.1M
BIIB icon
8
Biogen
BIIB
$30.7B
$61.8M 2.9%
186,783
+12,800
+7% +$4.22M
PFE icon
9
Pfizer
PFE
$142B
$56.2M 2.64%
2,004,962
+1,651,917
+468% +$46.4M
INCY icon
10
Incyte
INCY
$24.9B
$56M 2.63%
1,141,961
+373,723
+49% +$18.7M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$11.7B
$51.3M 2.4%
710,527
+289,143
+69% +$19M
VTRS icon
12
Viatris
VTRS
$20.7B
$46M 2.15%
1,010,105
+357,896
+55% +$17.4M
AGN
13
DELISTED
Allergan Inc
AGN
$40.7M 1.91%
228,227
+71,600
+46% +$11.9M
ILMN icon
14
Illumina
ILMN
$31B
$37.6M 1.76%
235,763
+129,014
+121% +$21.6M
TEVA icon
15
Teva Pharmaceuticals
TEVA
$41.2B
$35.1M 1.64%
652,194
+340,718
+109% +$18.1M
JNJ icon
16
Johnson & Johnson
JNJ
$617B
$34.9M 1.63%
+327,212
New +$33.9M
CBST
17
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$32.8M 1.54%
494,454
+230,682
+87% +$15.2M
TMO icon
18
Thermo Fisher Scientific
TMO
$214B
$32.5M 1.52%
266,875
+207,215
+347% +$25.2M
SHPG
19
DELISTED
Shire pic
SHPG
$31.9M 1.5%
123,322
– –
AET
20
DELISTED
Aetna Inc
AET
$31.5M 1.48%
389,031
+141,490
+57% +$11.5M
JAZZ icon
21
Jazz Pharmaceuticals
JAZZ
$16.2B
$27.8M 1.3%
173,241
+77,284
+81% +$11.9M
ABBV icon
22
AbbVie
ABBV
$455B
$27.8M 1.3%
+481,219
New +$26.7M
BMY icon
23
Bristol-Myers Squibb
BMY
$132B
$27.4M 1.28%
535,240
+332,640
+164% +$16.6M
AKRX
24
DELISTED
Akorn Inc
AKRX
$25.4M 1.19%
699,382
– –
IPXL
25
DELISTED
Impax Laboratories, Inc.
IPXL
$23.5M 1.1%
990,283
+645,600
+187% +$16.5M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, Tekla Capital Management held 110 positions worth $2.13B, up 96% from $1.09B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Tekla Capital Management deployed $940M of net new capital in Q3 2014, opening 45 new positions and adding to 37 existing holdings. Its largest new stake was Johnson & Johnson: 327,212 shares worth $34.9M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 89% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $2.11M trimmed.

  • Tekla Capital Management's largest Q3 2014 buy was Johnson & Johnson: 327,212 shares worth $34.9M.
  • Tekla Capital Management added most to Celgene Corp in Q3 2014, an estimated $98.6M increase.
  • Tekla Capital Management's biggest Q3 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $2.11M.
  • Tekla Capital Management fully exited FOREST LABORATORIES INC in Q3 2014, selling an estimated $10.9M.
  • Tekla Capital Management's ten largest holdings make up 47% of its $2.13B portfolio in Q3 2014.
  • Tekla Capital Management opened 45 new positions and closed 2 in Q3 2014.
  • Tekla Capital Management's portfolio value rose 96% quarter-over-quarter to $2.13B.

Based on Tekla Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.